FR2777191A1 - USE OF AN EXTRACT OF AT LEAST ONE PLANT FROM THE FAMILY OF COMPOUNDS, GENUS BELLIS - Google Patents

Abstract

The invention concerns the use in or for preparing a composition of at least a plant extract of the Compositae family, such as the genus Bellis as antagonist of the vasoactive intestinal peptide or V.I.P. The invention also concerns the use of said extract in or for preparing a composition, the extract or the composition being for reducing perspiration.

Description

1 2777191

  The subject of the invention is the use, as active principle, in or for the preparation of a composition of at least one extract of at least one plant from the family of Compounds, genus Bellis as an antagonist vasoactive intestinal peptide or VlP (Vasoactive Intestinal Peptide). The invention further relates to the use, as active principle, of said extract in or for the preparation of a composition, the extract or composition being intended for treating disorders

  associated with an excess of synthesis and / or release of V.l.P ..

  The subject of the invention is also the use, as active principle, of said extract in or for the preparation of a composition, the extract or the composition being intended to reduce sweating. The invention finally relates to a method of

  cosmetic treatment to improve personal hygiene.

  V.I.P. is a polypeptide chemical element developed and released by a cell

  endocrine or by a nerve fiber. The V.I.P. is made up of 28 amino acids.

  It is part of the secretin family. Analysis of its sequence reveals a strong homology with this peptide as well as with glucagon and PACAP (pituitary adenylate cyclase activating polypeptide). The V.l. P. was first identified in the lung and intestine where it acts as a powerful vasodilator. High concentrations of V. l.P. were also found in the system

central and peripheral nervous system.

  In the central nervous system, the V.l.P. is involved in the control of metabolic energy (degradation of glycogen) and in the regulation of

  cerebral blood circulation by its vasodilatory activity.

  On the outskirts, the V.l.P. is present in many tissues where its functions can be diverse. It is often co-located in the parasympathetic nerve fibers with acetylcholine where its release potentiates the affinity of acetylcholine for its receptor. In addition to vasodilating activity on the vessels of many tissues, V.l.P. also has immunomodulatory functions (modulation of the migration and proliferation of T lymphocytes). It also plays a very important role in water and electrolyte exchanges. Many nerve fibers containing V.l.P. are present in the digestive tract (stomach,

  intestine, pancreas), urogenital tract or salivary glands. The V.l.P.

  also has muscle relaxant properties, particularly of the gastrointestinal tract

intestinal and bronchial tubes.

  The V.l.P. due to its vasodilatory properties is involved in erection.

  In the skin, nerve fibers V.l.P. positive are described around the eccrine sweat glands and around the sebaceous glands (Br. J. of

  Dermatol. 1990, 123, 65-76 - Japanese J. of Physiology 1987, 3, 929-936).

2 2777191

  The V.l.P. binds to two receptors, V.l.P. 1 and VIP 2 (Sreedharan et al. Biochemical and Biophysical Research Communications. 1993, vol. 2, 546-553.) Which are both coupled to a protein G. The binding of VIP to one or other of its receptors activate a G protein which in turn activates adenylate cyclase. The latter transforms Adenosine TriPhosphate (ATP) into cyclic Adenosine MonoPhosphate (cAMP) which then causes a cascade

  of intracellular biochemical events leading to the physiological effect.

  Due to the ubiquitous distribution of V.l.P. very many disorders are

  associated with an excess of synthesis and / or release of V.l.P ..

  The use of V.l.P. is one of the therapeutic alternatives

  effective in the treatment of all these disorders.

  For a substance to be recognized as a V.I.P. antagonist, it must meet one of the following characteristics: - the antagonist substance must be capable of inhibiting the formation

  adenosine 3 ': 5'-cyclic monophosphate (cAMP) induced by V.l.P.

  on its receptor in cultured cells (such as keratinocytes) the antagonist substance must be able to reduce the release

  histamine induced by V.l.P. During degranulation of mast cells.

  It is described in patent application WO95 / 21194, compositions containing V.I.P. antagonists. to inhibit the growth of tumor cells containing V.I.P. receptors, to induce the death of neuronal cells, to modify the circadian rhythm of mammals and to inhibit the division of neuroblastoma cells. US Patent 5,217,953 describes the use of antagonist

  of V.l.P. to change the sexual behavior of mammals.

  However, none of the above documents envisages or suggests that an extract from at least one plant from the Compositae family, genus Bellis, may have antagonistic activity against V.l.P. as defined above and therefore can be

  especially used as an active ingredient to treat the disorders indicated above

  above. In the prior art, plants of the family of Compounds, genus Bellis are known to be used in compositions intended to promote hair growth (SU 488589, SU1130347; RU2066992), in compositions

3 2777191

  anti-dandruff (RU2044538), in cosmetic compositions in the form of

  skin mask (RU2038070), in the form of an anti-aging cream

  inflammatory (SUl1123696, SU1799593, RU2026669, RU2026667), moisturizer (SU1724242, RU2026668). None of these documents describes plants of the Compositae family, genus Bellis, as the only active ingredient. And, to the knowledge of the applicant, the antagonistic activity of the V.l.P. that plants of the Compositae family, genus Bellis have never been described. The Applicant has discovered that an extract of at least one plant from the family of Compounds, genus Bellis meets the characteristics defined as characterizing a V.l. P. and can therefore be used as an antagonist

of V.L.P ..

  The subject of the invention is therefore the use, as active principle, in or for the preparation of a composition of an effective amount of at least one extract of at least one plant from the family of Compounds, genus Bellis as an antagonist

of V.L.P ..

  By active principle is meant any molecule or extract capable of modifying or

  to modulate the functioning of at least one given biological system.

  The extract of at least one plant from the family of Compounds, genus Bellis can be any extract prepared from any plant material derived from at least one plant from

  the Compound family, genus Bellis.

  Thus, the extract of at least one plant from the family of Compounds, genus Bellis used according to the invention can be obtained from plant material obtained from a whole plant or part of a plant such as the leaves, the stems, the buds flowers (flower buds), flowers, petals, roots or undifferentiated cells. By undifferentiated plant cells is meant any plant cell having none of the characteristics of a particular specialization and capable of living by itself and not in dependence on other cells. These undifferentiated plant cells are possibly able, under the effect of an induction, to

  any differentiation consistent with their genome.

4 2777191

  According to the chosen culture method, and in particular according to the chosen culture medium, it is possible to obtain, from the same explant, plant cells

  undifferentiated with different characters.

  Preferably according to the invention, floral tops are used. The extract of at least one plant from the family of Compounds, genus Bellis can be any extract prepared from any plant material derived from at least one plant from

  the family of Compounds, genus Bellis cultivated in vivo or from in vitro culture.

  By in vivo culture is meant any conventional type culture, that is to say in soil at

  in the open air or in a greenhouse, or even above ground.

  The term “in vitro culture” means all of the techniques known to those skilled in the art which artificially allow a plant or a part to be obtained.

  of a plant. The selection pressure imposed by the physical-

  chemicals during the growth of plant cells in vitro makes it possible to obtain a standardized plant material and available throughout the year unlike

plants grown in vivo.

  Preferably, according to the invention, a plant originating from culture in vivo is used.

  Any extraction method known to those skilled in the art can be used to

  prepare the extract contained in the composition according to the invention.

  Mention may in particular be made of aqueous extracts, alcoholic extracts or those using an organic solvent.

  The term “aqueous solvent” means any solvent consisting wholly or partly of water.

  Mention may thus be made of water itself, hydroalcoholic solvents in any proportion or else solvents consisting of water and a compound such as

  propylene glycol in any proportion.

  Mention may in particular be made, among alcoholic solvents, of ethanol.

  It is also possible to use an extract prepared by the method described in the

  French patent application No. 95-02379 filed by the applicant.

  Thus, in a first step, the plant material is ground in a cold aqueous solution, in a second step, the particles in suspension are removed from the aqueous solution resulting from the first step, and in a

2777191

  third step, the aqueous solution from the second step is sterilized. This

  aqueous solution corresponds to the extract.

  On the other hand, the first step can advantageously be replaced by a simple freezing operation of the plant tissues (for example at 20 ° C.), followed by an aqueous extraction repeating the second and third steps described above. Whatever the mode of preparation used according to the invention, subsequent steps aimed at promoting conservation and / or stabilization can be added without modifying the very nature of the extract. Thus, for example, the extract obtained can be lyophilized by any conventional lyophilization method. A powder is thus obtained which can be used directly or

  mix well in a suitable solvent before use.

  Preferably, according to the invention an aqueous extract is used and even more preferably an extract produced with a solvent composed of water and propylene glycol, such as for example the Herbasol sold by the company

COSMETOCHEM (Grasse, France).

  We have previously seen in the text examples of disorders linked to an excess

  synthesis and / or release of V.l.P ..

  A further subject of the invention is the use, as active principle, in or for the preparation of a composition of an effective amount of an extract of at least one plant from the family of Compounds, like Bellis, the extract or composition being intended to treat disorders associated with an excess of synthesis and / or

release of V.L.P ..

  Thus, according to a particular aspect, the invention relates to the use as active ingredient, in or for the preparation of a composition of an effective amount of an extract of at least one plant from the family of Compounds, like Bellis, the extract or composition being intended to treat disorders of the central nervous system, respiratory disorders, cardiovascular disorders, vasospastic disorders, gastrointestinal disorders, skin disorders, disorders of the tract urogenital, allergic syndromes or

immunological disorders.

6 2777191

  In the field of skin disorders, it is known that nerve fibers V.l.P. positive are present in the skin around the glands

  eccrine sweat and to a lesser extent around the sebaceous glands.

  In addition, specific V.I.P. receptors have been characterized on the secretory cells of the human eccrine sweat glands. A close correlation has been reported between the release of V.I.P. by the nerve fibers around the eccrine sweat glands and an effect of this V.I.P. on sweat secretion. We know that some people suffer from hypersecretion of the eccrine sweat glands, which can lead to unpleasantness (excessive sweating, bad smells, etc.). So we understand the usefulness of having

  compounds and / or compositions having antiperspirant activity.

  The plant extract from the Composites family, genus Bellis, due to its anti-V.I.P. activity. can therefore be used to combat hypersecretion of

sweat glands.

  The invention therefore relates more particularly to the use, as active principle, in or for the preparation of a composition of an effective amount of at least one extract of at least one plant from the family of Compounds, genus Bellis, the extract or composition being intended to treat hypersecretion of the sweat glands. The family of Compounds, genus Bellis comprises 5 species namely Bellis annua,

  Bellis perennis, Bellis silvestris, Bellis pumila and Bellis pappulosa.

  Thus, the plant extract from the family of Compounds, genus Bellis of the invention is an extract prepared from material obtained from at least one plant belonging to a species chosen from Bellis annua, Bellis perennis, Bellis silvestris, Bellis

pumila and Bellis pappulosa.

  Preferably according to the invention, the plant belongs to the species Bellis perennis.

  According to the invention, the amount of extract of at least one plant from the family of Compounds, genus Bellis used in the composition is of course a function of

  The desired effect and can therefore vary to a large extent.

  To give an order of magnitude, the extract can be in an amount representing from 0.001% to 20% of the total weight of the composition and preferably in one

7 2777191

  amount representing from 0.01% to 10% of the total weight of the composition.

  The present invention also relates to a composition for personal hygiene comprising, as active principle, at least one plant extract from the family of Compounds, genus Bellis. In particular, the composition of the invention is a composition for reducing

  hypersecretion of the sweat glands.

  The composition of the invention can be a cosmetic or pharmaceutical composition. The present invention further relates to a cosmetic treatment process with a view to reducing the hypersecretion of the sweat glands, characterized in that it is used by application on the skin, on the hair, and / or on the mucous membranes, a cosmetic composition comprising at least one extract of at least one plant from the family of Compounds, genus Bellis in a medium

cosmetically acceptable.

  2o By cosmetically acceptable medium is meant compatible with the skin, the

  scalp, mucous membranes, nails, and hair.

  The cosmetic treatment process of the invention can be implemented in particular by applying hygienic or cosmetic compositions such as

  defined above, according to the usual technique for using these compositions.

  For example: application of creams, gels, serums, lotions, cleansing milks or sunscreen compositions or compositions

for spray.

  Whatever the form of the composition according to the invention, the amount of extract of at least one plant from the family of Compounds, genus Bellis used in the composition is of course dependent on the desired effect and can therefore vary in

to a large extent.

8 2777191

  Whatever the form of the composition according to the invention in which at least one extract of at least one plant from the family of Compounds, genus Bellis is used, it can be ingested, injected or applied to the skin (on any skin area of the body), hair, nails or mucous membranes (buccal, jugale, gingival, genital, conjunctiva). According to the mode of administration, the composition according to the invention can be presented in all the galenical forms

normally used.

  For topical application to the skin, the composition may take the form in particular of an aqueous or oily solution or of a dispersion of the lotion or serum type, of emulsions of liquid or semi-liquid consistency of the milk type, obtained by dispersion of a phase oily in an aqueous phase (O / W) or vice versa (W / O), or of suspensions or emulsions of soft consistency of the aqueous or anhydrous cream or gel type, or of microcapsules or microparticles, or of vesicular dispersions of the ionic type and / or non-ionic. These compositions are

  prepared according to the usual methods.

  They can also be used for the hair in the form of aqueous, alcoholic or hydroalcoholic solutions, or in the form of creams, gels, emulsions, foams or also in the form of aerosol compositions.

  also comprising a pressurized propellant.

  For injection, the composition may be in the form of an aqueous, oily lotion or in the form of a serum. For the eyes, it can be in the form of drops and for ingestion, it can be in the form of

  capsules, granules of syrups or tablets.

  The amounts of the various constituents of the compositions according to the invention are

  those conventionally used in the fields considered.

  These compositions constitute in particular cleansing, protective, treatment or care creams for the face, for the hands, for the feet, for large anatomical folds or for the body (for example day creams, night creams, make-up remover creams, foundation creams, sunscreen creams), fluid foundations, make-up removal milks, body protection or care milks, anti-sun milks, lotions, gels or foams for care of the skin, such as cleansing lotions, sunscreen lotions, artificial tanning lotions, bath compositions, compositions

9 2777191

  deodorants comprising a bactericidal agent, gels or lotions after

  shaving, depilatory creams, compositions against insect bites, pain relieving compositions, compositions for treating certain skin diseases such as eczema, rosacea, psoriasis, lichens, severe pruritus. The compositions according to the invention can also consist of

  solid preparations constituting soaps or cleaning bars.

  The compositions can also be packaged in the form of a composition

  for aerosol also comprising a propellant under pressure.

  The composition according to the invention may also be a composition for hair care, and in particular a shampoo, a styling lotion, a treating lotion, a styling cream or gel, a composition of dyes (in particular oxidation dyes) in the form of coloring shampoos, restructuring hair lotions, a perm composition (in particular a composition for the first time of a perm), a fall prevention lotion or gel, an antiparasitic shampoo, etc. When the composition is an emulsion, the proportion of the fatty phase can range from 5% to 80% by weight, and preferably from 5% to 50% by weight relative to the total weight of the composition. The oils, waxes, emulsifiers and coemulsifiers used in the composition in the form of an emulsion are chosen from those conventionally used in the cosmetic field. The emulsifier and the coemulsifier are present in the composition in a proportion ranging from 0.3% to 30% by weight, and preferably from 0.5 to 20% by weight relative to the total weight of the composition. The emulsion may, in addition, contain lipid vesicles. When the composition is an oily solution or gel, the fatty phase may

  represent more than 90% of the total weight of the composition.

  In a known manner, the cosmetic composition may also contain adjuvants customary in the cosmetic field, such as hydrophilic or lipophilic gelling agents, hydrophilic or lipophilic additives, preservatives, antioxidants, solvents, perfumes, fillers, filters, odor absorbers and coloring matters. The quantities of these various adjuvants are

2777191

  those conventionally used in the cosmetic field, and for example from 0.01% to 10% of the total weight of the composition. These adjuvants, depending on their nature, can be introduced into the fatty phase, into the aqueous phase and / or into

lipid spherules.

  As oils or waxes which can be used in the invention, mention may be made of mineral oils (petroleum jelly oil), vegetable oils (liquid fraction of shea butter, sunflower oil), animal oils (perhydrosqualene), synthetic oils ( Purcellin oil), silicone oils or waxes (cyclomethicone) and

  fluorinated oils (perfluoropolyethers), beeswax, carnauba or paraffin.

  Fatty alcohols and fatty acids (stearic acid) can be added to these oils.

  As emulsifiers which can be used in the invention, there may be mentioned for example glycerol stearate, polysorbate 60 and the mixture of PEG6 / PEG-32 / Glycol

  Stearate sold under the name of TefoseR 63 by the company Gattefosse.

  As solvents which can be used in the invention, mention may be made of lower alcohols,

  in particular ethanol and isopropanol, propylene glycol.

  As hydrophilic gelling agents which can be used in the invention, mention may be made of carboxyvinyl polymers (carbomer), acrylic copolymers such as acrylate / alkylacrylate copolymers, polyacrylamides, polysaccharides such as hydroxypropylcellulose, natural gums and clays, and, as lipophilic gelling agents, mention may be made of modified clays such as bentones, metal salts of fatty acids such as aluminum stearates and silica

  hydrophobic, ethylcellulose, polyethylene.

  The composition may contain other hydrophilic active agents such as proteins or protein hydrolysates, amino acids, polyols, urea, allantoin, sugars and sugar derivatives, water-soluble vitamins, plant extracts

and hydroxy acids.

  As lipophilic active agents, retinol (vitamin A) and its derivatives, tocopherol (vitamin E) and its derivatives, essential fatty acids, ceramides, can be used.

  essential oils, salicylic acid and its derivatives.

  According to the invention, the composition can combine at least one extract of at least one plant from the family of Compounds, of the Bellis genus with other active agents intended for the prevention and / or treatment of skin conditions. Among these active agents, there may be mentioned by way of example: - agents modulating differentiation and / or proliferation and / or skin pigmentation such as retinoic acid and its isomers, retinol and its esters, vitamin D and its derivatives, estrogens such as estradiol, kojic acid or hydroquinone; antibacterials such as clindamycin phosphate, erythromycin or antibiotics of the tetracycline class; - antiparasitics, in particular metronidazole, crotamiton or o pyrethroids; - antifungals, in particular compounds belonging to the class of imidazoles such as econazole, ketoconazole or miconazole or their salts, polyene compounds, such as amphotericin B, compounds of the allylamine family, such as terbinafine, or octopirox; - antiviral agents such as acyclovir; - steroidal anti-inflammatory agents, such as hydrocortisone, valerate

  betamethasone or clobetasol propionate, or

  non-steroidal inflammatory drugs such as ibuprofen and its salts, diclofenac and its salts, acetylsalicylic acid, acetaminophen or glycyrrhetinic acid; - anesthetic agents such as lidocaine hydrochloride and its derivatives; - antipruritic agents such as thenaldine, trimeprazine or cyproheptadine;

  - keratolytic agents such as alpha- and beta-acids

  hydroxycarboxylic or beta-ketocarboxylic, their salts, amides or esters and more particularly hydroxy acids such as glycolic acid, lactic acid, salicylic acid, citric acid and in general fruit acids, and n-octanoyl-5salicylic acid; - anti-free radical agents, such as alphatocopherol or its esters, superoxide dismutases, certain metal chelators or ascorbic acid and its esters; - antiseborrheics such as progesterone; - anti-dandruff agents such as octopirox or zinc pyrithione; - anti-acne drugs such as retinoic acid or benzoyl peroxide;

  - plant or microbial extracts.

  The following examples and compositions illustrate the invention without limiting it in any way. In the compositions the proportions indicated are

percentages by weight.

12 2777191

Example 1

  Preparation of an extract of Bellis perennis: 100 g of dried flowers of Bellis perennis are crushed in a flail mill, equipped with a sieve of 1 mm in diameter. These 100 g of ground material are then macerated in 1 liter of demineralized water for 15 minutes at 4 C. (bath of

  ice). The preparation thus obtained is filtered at 0.22 μm (sterilizing filtration).

  The extract thus prepared is stored at 4 C. The extract obtained can be lyophilized.

  The cold treatment makes it possible to freeze the enzymatic activities, the sterilizing filtration avoids the degradation of the active ingredients by the microorganisms of the environment. Finally, the water vehicle facilitates cosmetic or pharmaceutical formulations. Example 2: Pharmacological activity of an extract of Bellis perennis: 1) Receptive affinity test: This test is carried out on cells of the HT-29 line (human colon adenocarcinoma) (Biochem. J., 1985, vol. 231, p 139-143). The cells are seeded at 40,000 cells / cm 2 in a 25 cm 2 flask in DMEM medium (sold by the company Gibco BRL) containing 10% fetal calf serum and incubated at 37 ° C. in CO2 / air atmosphere (1: 9). The cells are recovered after 4 to 5 days (in the exponential growth phase) using a 0.13 M phosphate pH 7.2 saline solution containing 3 mM EDTA. They are centrifuged at 2000 g

  for 5 min at 4 C. The pellet is taken up in a 5 mM hypo Hepes buffer.

  osmotic at pH 7.5. After 15 min. in ice, the suspension is homogenized. The homogenate is then centrifuged at 30,000 g for 10 min. The pellet is washed three times with a 60 mM Hepes buffer, pH 7.5. The membrane preparation thus obtained is stored at -80 C; proteins are dosed

  according to the Bradford method (with BSA as standard).

  The test consists in incubating the preceding membrane preparation (approximately 100 μg / ml) for 60 minutes at 30 ° C. in the presence of '251-V.I.P. (and other compounds if necessary) in Hepes buffer 60 mM pH 7.5 containing 2% bovine serum albumin and 0.1% bacitracin. The reaction is stopped by transferring the incubation medium to cold buffer. The V.l.P. radioactive linked to the membrane preparation is then separated by centrifugation at 30,000 g for 10 min at

  4 C then the radioactivity is measured using a scintillation counter.

13 2777191

  The measurement of the receptive affinity of Bellis perennis extract for the V.l.P. receptor is demonstrated by adding doses to the incubation medium

of the extract.

  The decreasing values of radioactivity measured reflect a competition on the receptor between the radiolabelled natural ligand, 1251-V. I.P., and

Bellis perennis extract.

  The extract of Example 1 (at 10% of flower heads crushed per equivalent volume of water) and a commercial extract called Herbasol sold by the company COSMETOCHEM (at 5% of flower heads crushed per volume of mixture

  propylene glycol / water / phenonix) were tested in parallel.

  The IC50 values (concentration inhibiting 50% of the specific binding of the natural ligand for its receptor) obtained with the two extracts are presented in the table below IC50 Herbasol extract of Bellis perrenis 1.2 Aqueous extract of Bellis perrenis 2, 8 These results clearly show an affinity for Bellis extract

  perennis, whatever the preparation method for the V.l. P.

  2) Measurement of the increase in the rate of AMPcyclic (cAMP) induced by V. l.P.

  effect of an extract of Bellis perrenis.

  This test is carried out on primary cultures of keratinocytes derived from glandular cells. The cells are cultured in KGM (Keratinocytes Growth Medium) medium at 37 ° C. in an atmosphere containing 5% of CO2. They are seeded at 20,000 cells / cm2 in 24-well plates and used between 3 and 7 days after seeding. The test consists in incubating the cells in the usual culture medium for min at 37 ° C. in the presence of V.l.P. (and / or other compounds) and an agent blocking the degradation of cAMP such as 1'-isobutyl-1-methylxanthine (IBMX). The reaction is stopped by adding perchloric acid (70%, 11N) and the cAMP produced is measured in the supernatant by an immunoenzymatic method (Amersham cAMP EIA System RPN 225 kit). The dosage is based on the competition

14 2777191

  between cAMP produced by cells and a given amount of cAMP coupled to peroxidase, for a limited number of cAMP binding sites. The amount of cAMP coupled to the peroxidase linked to the sites is revealed by the addition of a substrate (tetramethylbenzidine hydrogen peroxide) and measured by spectrophotometric reading. The amount of cAMP to be assayed in the culture supernatant will therefore be inversely proportional to the amount of cAMP coupled to the

peroxidase thus measured.

  This complementary test of the affinity test makes it possible to highlight not only a competition between the V.l.P. and the sample to be tested for the receiver

  at V.l.P., but also an agonist or antagonist effect.

  The extract of Example 1 and a commercial extract called Herbasol (sold by

  COSMETOCHEM's were tested in 2 parallel experiments.

  The results presented in the table below are expressed as a percentage

  inhibition of the specific binding of the natural ligand.

  pmole of cAMP / 10,000 cells Culture medium 7.4 V.l.P. (10-6M) 25.6 V.l.P. (10-6M) + Herbasol de Be / lily perrenis 5.8 (at 10% dry matter) _ _ _ _ _ _ _ _ _ _ _ _ _ ___ pmole of cAMP / 10,000 cells Culture medium 1.08 VlP (10'M) 10.51 V.l.P. (10-6M) + aqueous extract of Bellis perrenis 4.27 (at 5% dry matter) (example 1) These results demonstrate that the extract of Bellis perrenis, whatever its mode of

  preparation, acts as a V.L.P antagonist.

2777191

Example 3:

  Examples of compositions comprising at least one extract of at least one plant from the family of Compounds, genus Bellis illustrating the invention. These compositions, unless otherwise indicated, are obtained by simple mixing of the various ingredients: Composition 1: Aqueous antiperspirant cream (oil / water) (CTFA nomenclature) Phase A: fatty - Cetearyl alcohol (fatty substance, gelling agent) 4.00% - Stearate glycerol (fatty substance, gelling agent) 2.50% - Steareth-25 (emulsifier) 1.05% - Stearyl alcohol (fatty substance, gelling agent) 1.05% - Ceteareth-33 (emulsifier) 1.00% - Dimethicone 1, 00% - Ceteth-20 (emulsifier) 0.40% Preservative qs Phase B: aqueous - Herbasol de Be / lily perrenis 5.00% Preservative qs - Water qs 100% Phase C: - Fragrance qs - Bactericide qs Phase D: - Talc 1.00% Procedure: Heat phase B to 70-80 C, with stirring. Heat phase A to 70-80 C. When the two phases are well homogeneous, incorporate A into B, with vigorous stirring for 10 min. Cool with weaker stirring. At C, add the premixed phase C. Shake vigorously for 5 min. Cool with weaker stirring. Around 30 C, slowly incorporate phase D.

  Continue cooling to room temperature.

  We obtain a supple and soft cream, with a spreading powder effect providing a

  effective protection against perspiration.

16 2777191

  Composition 2: Anhydrous antiperspirant cream (CTFA nomenclature) Phase A: - Stearalkonium hectorite (gelling agent) 4.20% - Propylene carbonate (suspending agent) 1.40% - Caprylic / Capric Triglycerides 29.40% Dimethicone 5.00 % - Isohexadecane (solvent) qs 100% Phase B: Herbasol de Bellis perrenis 3.00% O10 - Talc 1.00% Phase C: - Fragrance qs Phase D: - Talc 6.00%

  Procedure: Mix the phase A compounds at room temperature.

  Then incorporate phase C, still at room temperature. When everything is

  homogeneous, incorporate B and D slowly.

  The cream obtained is particularly soft, non-greasy, non-sticky, and provides by its dry impact, a feeling of greater security against

axillary humidity.

  Composition 3: Aerosol (CTFA nomenclature) Phase A: -Cyclomethicone qs 100% - Quaternium-18 bentonite 3.00% - Triethyl citrate 7.00% Dimethiconol 1.40% - Isopropyl palmitate 6.00% Phase B: - Herbasol de Bellis perrenis 5.00% Phase C: - Talc 1.50% Procedure: Mix the ingredients of phase A cold. Slowly add aluminum chlorohydrate, then talc. Mix vigorously

1 7 2777191

  to obtain a homogeneous suspension. The latter can then be

  pressurized as follows: 13% juice, 87% compressed or liquefied gas.

  The juice delivered leaves a soft, powdery impact on the skin providing protection against perspiration. Composition 4: Compacted powder Magnesium chloride (antiperspirant) 5.00% - Kaolin 10.00% Herbasol de Bellis perrenis 5.00% - Perfume 0.30% - Talc qs 100% Composition 5: Deodorant stick - Herbasol E) Bellis perrenis 8.00% Stearyl alcohol 24.00% - PEG-400 distearate 6.00% - Hydrocarbon wax 4.00% - Cyclomethicone 46.00%

18 2777191

Claims (13)

  1. Use, as active principle, in or for the preparation of a composition, of an effective amount of at least one extract of at least one plant from the family of Compounds, genus Bellis as an antagonist of the VlP. 2. Use, as active principle, in or for the preparation of a composition, of an effective amount of at least one extract of at least one plant from the family of Compounds, genus Bellis, the extract or the composition being intended to treat disorders associated with an excess of synthesis and / or release of Vl P .. 3. Use, as active principle, in or for the preparation of a composition, of an effective amount of at least one extract of at least one plant from the family of Compounds, genus Bellis, the extract or the composition being intended to treat disorders of the central nervous system, respiratory disorders,   cardiovascular disorders, vasospastic disorders, gastrointestinal disorders   intestinal, skin disorders, disorders of the urogenital tract,   allergic syndromes or immunological disorders.   4. Use, as active principle, in or for the preparation of a composition of an effective amount of at least one extract of at least one plant from the family of Compounds, genus Bellis, the extract or the composition being intended for   treat hypersecretion of the sweat glands.   5. Use according to any one of claims 1 to 4, characterized by the   the fact that the extract of at least one plant from the family of Compounds, genus Bellis is obtained from plant material obtained from whole plants or from leaves, stems,   flowers, petals, roots or undifferentiated cells.   6. Use according to claim 5, characterized in that the extract of at least one plant from the family of Compounds, genus Bellis is obtained from   floral tops (flower buds).   7. Use according to any one of claims 1 to 6, characterized by the   fact that the extract of at least one plant from the family of Compounds, genus Bellis is obtained from plant material obtained from at least one plant from the family of   Compounds, genus Bellis cultivated in vivo. 19 2777191   8. Use according to any one of claims 1 to 7, characterized by the   fact that in the composition the extract of at least one plant from the family of Compounds, genus Bellis is in an amount representing from 0.001% to 20% of the total weight of the composition and preferably in an amount representing   0.05% to 10% of the total weight of the composition.   9. Use according to any one of claims 1 to 8, characterized by the   fact that the extract is an extract prepared from material obtained from at least one plant belonging to a species chosen from Bellis annua, Bellis perennis,   Bellis silvestris, Bellis pumila and Bellis pappulosa.   10. Use according to any one of claims 1 to 9, characterized by the   fact that the plant belongs to the species Bellis perennis.   11. Cosmetic or pharmaceutical composition for personal hygiene comprising, as active principle, at least one plant extract from the family of   Compounds, genus Bellis as defined in any one of claims 1 to 10.   12. Composition according to the preceding claim, characterized in that it   is intended to decrease the hypersecretion of the sweat glands.   13. Cosmetic treatment method with a view to reducing the hypersecretion of the sweat glands, characterized in that a cosmetic composition comprising at least one is used on the skin, on the hair, and / or on the mucous membranes. extract of at least one plant from the family of   Compounds, like Bellis in a cosmetically acceptable medium.